StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.69+0.28 (+1.06%)

Close on Nov 18, 2026Market cap $1.72BP/E –Yield –

Stoke Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Stoke Therapeutics's price to sales ratio was 62.8× on Nov 11, 2026, against 8.3× a year earlier. Over the last 4 years it ranged from 2.7× to 88.7×, with a median of 28.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202662.8×+54.3
2025Dec 31, 20258.5×−26.4
2024Dec 31, 202434.9×+9.7
2023Dec 29, 202325.2×–

More Stoke Therapeutics figures

See a number that looks wrong?